Title:
Diagnostic agent
Document Type and Number:
Japanese Patent JP6224067
Kind Code:
B2
Abstract:
The present invention relates to selective cancer treatment regimes based on assaying for the presence or absence of a glutamine or a nucleic acid that encodes glutamine at position 859 of the catalytic p110α subunit of PI3K; methods for producing a transmittable form of information for predicting the responsiveness of patient to (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof; and a kit thereof.
Inventors:
Furet, Pascal
Fritsch, Christine
Myra, Sober-Michael
Fritsch, Christine
Myra, Sober-Michael
Application Number:
JP2015502341A
Publication Date:
November 01, 2017
Filing Date:
March 27, 2013
Export Citation:
Assignee:
Novartis Age
International Classes:
A61K31/4439; A61K45/00; A61P35/00; A61P43/00; C12Q1/68
Domestic Patent References:
| JP2012502080A | ||||
| JP2011527342A |
Foreign References:
| WO2012016970A1 | ||||
| EP2377933A1 |
Other References:
Biochem. J.,2011年,438,p.53-62
Biochem. J.,2008年,414,p.383-390
Bioorg Med Cgem Lett,2012年 1月,22,p.876-880
Biochem. J.,2008年,414,p.383-390
Bioorg Med Cgem Lett,2012年 1月,22,p.876-880
Attorney, Agent or Firm:
Hiroshi Kobayashi
Norio Omori
Takayuki Imazato
Yasuhito Suzuki
Norio Omori
Takayuki Imazato
Yasuhito Suzuki